Luke and Ellery Mooneyham welcomed their daughter, Lynnley, into the world one year ago. At 10 weeks old, she had her first ...

CDKL5 deficiency disorder (CDD) is a rare X-linked developmental and epileptic encephalopathy characterised by early-onset, treatment-resistant seizures, profound neurodevelopmental impairment and a ...

Scientists at the Francis Crick Institute have found a new treatment target for CDKL5 deficiency disorder (CDD), one of the most common types of genetic epilepsy. CDD causes seizures and impaired ...

Scientists at the Francis Crick Institute have found a new treatment target for CDKL5 deficiency disorder (CDD), one of the most common types of genetic epilepsy. CDD causes seizures and impaired ...

LONDON--(BUSINESS WIRE)--The Loulou Foundation, a private foundation dedicated to the development of therapeutics for the neurodevelopmental condition CDKL5 Deficiency Disorder (CDD), announced today ...

EDINBURGH, Scotland--(BUSINESS WIRE)--Lario Therapeutics (‘Lario Tx’, or ‘the Company’), a biopharmaceutical company developing first-in-class precision medicines that are targeting disease-modifying ...

The mechanism behind a type of genetic epilepsy known as CDKL5 deficiency disorder has been elucidated, highlighting a potential target for novel therapeutic approaches. In a recent paper, researchers ...

Researchers at the Francis Crick Institute, UCL and MSD have identified a potential treatment target for a genetic type of epilepsy. Developmental and epileptic encephalopathies are rare types of ...

NDA filing acceptance enables opportunity to draw $30 million of additional cash under company’s credit financing agreement with Oaktree Capital Management, L.P. “The FDA’s acceptance of our NDA ...

Scientists have found a new treatment target for CDKL5 deficiency disorder (CDD), one of the most common types of genetic epilepsy. Scientists at the Francis Crick Institute have found a new treatment ...